CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
We had previously demonstrated the role of CD103 integrin on lung tumor-infiltrating lymphocyte (TIL) clones in promoting specific TCR-mediated epithelial tumor cell cytotoxicity. However, the contribution of CD103 on intratumoral T cell distribution and functions and the prognosis significance of TIL subpopulations in non–small cell lung carcinoma (NSCLC) have thus far not been systematically addressed. In this study, we show that an enhanced CD103+ TIL subset correlates with improved early stage NSCLC patient survival and increased intraepithelial lymphocyte infiltration. Moreover, our results indicate that CD8+CD103+ TIL, freshly isolated from NSCLC specimens, display transcriptomic and phenotypic signatures characteristic of tissue-resident memory T cells and frequently express PD-1 and Tim-3 checkpoint receptors. This TIL subset also displays increased activation-induced cell death and mediates specific cytolytic activity toward autologous tumor cells upon blockade of the PD-1–PD-L1 interaction. These findings emphasize the role of CD8+CD103+ tissue-resident memory T cells in promoting intratumoral CTL responses and support the rationale for using anti–PD-1 blocking Ab to reverse tumor-induced T cell exhaustion in NSCLC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further research revealed that the presence of CD103+CD8+ TILs is a positive prognostic marker in several cancers [269-272].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [270]
In the citing paper
“Previous studies demonstrated that enhanced CD8+CD103+ TRM TILs correlate with improved survival in patients with early stage NSCLC18 and with other types of cancer19.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [18]
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“types of advanced solid tumors, including NSCLC (43, 44).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 1×
“both molecules has been reported to transmit a death signal to T cells (40, 41).”
BackgroundUpregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331 · cited 5×
“Indeed, downregulation of SIP1 was observed in CD103CD8 TRM T cells (18) and appeared to be required for their retention in peripheral tissues (28).”
BackgroundInfluentialFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · cited 1×
“Among these inhibitory receptors, CTLA-4, PD-1, and Tim3 appeared to be associated with T cell exhaustion in chronic viral infections (35–38) and tumor progression (39).”
BackgroundPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111 · cited 1×
“In the latter and present studies, CD103 T cells expressed high levels of PD-1, which has been defined as a biomarker of tumor-specific T cells (33).”
BackgroundSkin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity
Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., & Kupper, T. S. (2012) · Nature · doi:10.1038/nature10851 · Cited by 891 · cited 1×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
Background
Cited by
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors
Duhen, T., Duhen, R., Montler, R., Moses, J., Moudgil, T., de Miranda, N. F., Goodall, C. P., Blair, T. C., Fox, B. A., McDermott, J. E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05072-0 · Cited by 938
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 880
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
Runx3 programs CD8+ T cell residency in non-lymphoid tissues and tumours
Milner, J. J., Toma, C., Yu, B., Zhang, K., Omilusik, K., Phan, A. T., Wang, D., Getzler, A. J., Nguyen, T., Crotty, S., et al. (2017) · Nature · doi:10.1038/nature24993 · Cited by 677
Cascone, T., William, W. N., Weissferdt, A., Leung, C. H., Lin, H. Y., Pataer, A., Godoy, M. C. B., Carter, B. W., Federico, L., Reuben, A., et al. (2021) · Nature Medicine · doi:10.1038/s41591-020-01224-2 · Cited by 618
Tissue-Resident T Cells and Other Resident Leukocytes
Masopust, D., & Soerens, A. G. (2019) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053214 · Cited by 608
The emerging role of resident memory T cells in protective immunity and inflammatory disease
Park, C. O., & Kupper, T. S. (2015) · Nature Medicine · doi:10.1038/nm.3883 · Cited by 517
Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)
Cossarizza, A., Chang, H., Radbruch, A., Abrignani, S., Addo, R., Akdis, M., Andrä, I., Andreata, F., Annunziato, F., Arranz, E., et al. (2021) · European Journal of Immunology · doi:10.1002/eji.202170126 · Cited by 531
Ganesan, A.-P., Clarke, J., Wood, O., Garrido-Martin, E. M., Chee, S. J., Mellows, T., Samaniego-Castruita, D., Singh, D., Seumois, G., Alzetani, A., et al. (2017) · Nature Immunology · doi:10.1038/ni.3775 · Cited by 528
Understanding subset diversity in T cell memory
Jameson, S. C., & Masopust, D. (2018) · Immunity · doi:10.1016/j.immuni.2018.02.010 · Cited by 523
“tumor infiltrating lymphocytes (putatively TRM) correlates with favorable prognosis in bladder, ovarian, breast and lung cancers (Djenidi et al., 2015; Wang et al., 2015; Wang et al., 2016; Webb et al., 2014).”
Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
Durgeau, A., Virk, Y., Corgnac, S., & Mami-Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00014 · Cited by 495
“org January 2018 | Volume 9 | Article 14 of cytokines leading to weak antitumor reactivity (143, 144); for review, see Ref.”
BackgroundSelf-citationCD8+ T cells in the cancer-immunity cycle
Giles, J. R., Globig, A.-M., Kaech, S. M., & Wherry, E. J. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.005 · Cited by 449
Bremnes, R. M., Busund, L.-T., Kilvær, T. L., Andersen, S., Richardsen, E., Paulsen, E. E., Hald, S., Khanehkenari, M. R., Cooper, W. A., Kao, S. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.015 · Cited by 502
“High CD8 count is significantly associated with increased DFS No Djenidi et al. (2015)76 101 ADC, SCC, NOS I CD3, CD8, CD103 Intraepithelial and stromal WS CD103 TILs have pos PI, promoting CTL. CD8CD103 TILs lead to activation-induced cell death.”
BackgroundA pan-cancer single-cell panorama of human natural killer cells
Tang, F., Li, J., Qi, L., Liu, D., Bo, Y., Qin, S., Miao, Y., Yu, K., Hou, W., Li, J., et al. (2023) · Cell · doi:10.1016/j.cell.2023.07.034 · Cited by 450
Edwards, J., Wilmott, J. S., Madore, J., Gide, T. N., Quek, C., Tasker, A., Ferguson, A., Chen, J., Hewavisenti, R., Hersey, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2257 · Cited by 431
Krishna, C., DiNatale, R. G., Kuo, F., Srivastava, R. M., Vuong, L., Chowell, D., Gupta, S., Vanderbilt, C., Purohit, T. A., Liu, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.007 · Cited by 432
New insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
“Although immune checkpoint blockers (anti-PD-1, anti-PD-L1, anti-CTLA-4) on T cells result in significantly improved survival in various metastatic cancer types [non-small-cell lung cancers (NSCLC), melanoma, renal carcinoma, bladder carcinoma, head and neck squamous cell carcinoma (HNSCC), and lymphoma] (Ansell, 2017…”
BackgroundInfluentialTissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin
Park, S. L., Buzzai, A., Rautela, J., Hor, J. L., Hochheiser, K., Effern, M., McBain, N., Wagner, T., Edwards, J., McConville, R., et al. (2019) · Nature · doi:10.1038/s41586-018-0812-9 · Cited by 375
Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity
Park, J., Hsueh, P.-C., Li, Z., & Ho, P.-C. (2023) · Immunity · doi:10.1016/j.immuni.2022.12.008 · Cited by 371
Prospects for gene-engineered T cell immunotherapy for solid cancers
Klebanoff, C. A., Rosenberg, S. A., & Restifo, N. P. (2016) · Nature Medicine · doi:10.1038/nm.4015 · Cited by 365
Lim, C. J., Lee, Y. H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T. K. H., Yeong, J., Toh, H. C., Lee, S. Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316510 · Cited by 357
Rotte, A., Jin, J. Y., & Lemaire, V. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx686 · Cited by 344
Resident memory T cells, critical components in tumor immunology
Mami-Chouaib, F., Blanc, C., Corgnac, S., Hans, S., Malenica, I., Granier, C., Tihy, I., & Tartour, E. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0399-6 · Cited by 327
“The CD69 molecule downregulates expression of S1PR1, which favors the exit of T cells from tissues [37].”
BackgroundInfluentialSelf-citationT cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
Chandran, S. S., & Klebanoff, C. A. (2019) · Immunological Reviews · doi:10.1111/imr.12772 · Cited by 323
Induction of resident memory T cells enhances the efficacy of cancer vaccine
Nizard, M., Roussel, H., Diniz, M. O., Karaki, S., Tran, T., Voron, T., Dransart, E., Sandoval, F., Riquet, M., Rance, B., et al. (2017) · Nature Communications · doi:10.1038/ncomms15221 · Cited by 308
Durable and controlled depletion of neutrophils in mice
Boivin, G., Faget, J., Ancey, P.-B., Gkasti, A., Mussard, J., Engblom, C., Pfirschke, C., Contat, C., Pascual, J., Vazquez, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16596-9 · Cited by 300
Tissue-resident memory T cells in breast cancer control and immunotherapy responses
Byrne, A., Savas, P., Sant, S., Li, R., Virassamy, B., Luen, S. J., Beavis, P. A., Mackay, L. K., Neeson, P. J., & Loi, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0333-y · Cited by 301
Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy
Rosato, P. C., Wijeyesinghe, S., Stolley, J. M., Nelson, C. E., Davis, R. L., Manlove, L. S., Pennell, C. A., Blazar, B. R., Chen, C. C., Geller, M. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08534-1 · Cited by 304
Enamorado, M., Iborra, S., Priego, E., Cueto, F. J., Quintana, J. A., Martínez-Cano, S., Mejías-Pérez, E., Esteban, M., Melero, I., Hidalgo, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16073 · Cited by 293
Tissue-resident memory T cells at the center of immunity to solid tumors
Amsen, D., van Gisbergen, K. P. J. M., Hombrink, P., & van Lier, R. A. W. (2018) · Nature Immunology · doi:10.1038/s41590-018-0114-2 · Cited by 278
Resident memory T cells in the skin mediate durable immunity to melanoma
Malik, B. T., Byrne, K. T., Vella, J. L., Zhang, P., Shabaneh, T. B., Steinberg, S. M., Molodtsov, A. K., Bowers, J. S., Angeles, C. V., Paulos, C. M., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aam6346 · Cited by 278
Yi, Q., Xu, Z., Thakur, A., Zhang, K., Liang, Q., Liu, Y., & Yan, Y. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106733 · Cited by 241
Workel, H. H., Lubbers, J. M., Arnold, R., Prins, T. M., van der Vlies, P., de Lange, K., Bosse, T., van Gool, I. C., Eggink, F. A., Wouters, M. C. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0517 · Cited by 262
Host tissue determinants of tumour immunity
Salmon, H., Remark, R., Gnjatic, S., & Merad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 253
Effector, Memory, and Dysfunctional CD8+T Cell Fates in the Antitumor Immune Response
Reiser, J., & Banerjee, A. (2016) · Journal of Immunology Research · doi:10.1155/2016/8941260 · Cited by 255
“Clinical studies have shown a positive correlation between the frequency of CD8 + TILs and cancer-free survival in patients with breast, lung, melanoma, colorectal, and brain cancer [8–12].”
Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances
Zhao, L., Jin, S., Wang, S., Zhang, Z., Wang, X., Chen, Z., Wang, X., Huang, S., Zhang, D., & Wu, H. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01947-5 · Cited by 218
Tumour-infiltrating lymphocytes: from prognosis to treatment selection
Brummel, K., Eerkens, A. L., de Bruyn, M., & Nijman, H. W. (2023) · British Journal of Cancer · doi:10.1038/s41416-022-02119-4 · Cited by 242
Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer
Clarke, J., Panwar, B., Madrigal, A., Singh, D., Gujar, R., Wood, O., Chee, S. J., Eschweiler, S., King, E. V., Awad, A. S., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20190249 · Cited by 256
Menares, E., Gálvez-Cancino, F., Cáceres-Morgado, P., Ghorani, E., López, E., Díaz, X., Saavedra-Almarza, J., Figueroa, D. A., Roa, E., Quezada, S. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12319-x · Cited by 237
Hallmarks of response to immune checkpoint blockade
Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 238
“Studies incorporating these techniques have revealed a broad range of infiltrating lymphocytes far beyond the dichotomous effector and regulatory T lymphocyte subsets, and have highlighted their complex regulatory potential as well as potential plasticity (Iida et al, 2011; Djenidi et al, 2015).”
BackgroundChew, V., Lai, L., Pan, L., Lim, C. J., Li, J., Ong, R., Chua, C., Leong, J. Y., Lim, K. H., Toh, H. C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706559114 · Cited by 248
“This observation is consistent with previous reports that high abundance of CD45RO memory-CD8 T cells and TRMs are associated with good prognosis in several types of cancer (1, 38).”
ResultVirassamy, B., Caramia, F., Savas, P., Sant, S., Wang, J., Christo, S. N., Byrne, A., Clarke, K., Brown, E., Teo, Z. L., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.01.004 · Cited by 230
Tumor-reprogrammed resident T cells resist radiation to control tumors
Arina, A., Beckett, M., Fernandez, C., Zheng, W., Pitroda, S., Chmura, S. J., Luke, J. J., Forde, M., Hou, Y., Burnette, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11906-2 · Cited by 229
T cells and the skin: from protective immunity to inflammatory skin disorders
Ho, A. W., & Kupper, T. S. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0162-3 · Cited by 241
Tissue-resident memory T cells in tumor immunity and immunotherapy
Okła, K., Farber, D. L., & Zou, W. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201605 · Cited by 228
Targeting immune cells for cancer therapy
Gun, S. Y., Lee, S. W. L., Sieow, J. L., & Wong, S. C. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101174 · Cited by 229
Memory CD8+ T cell responses to cancer
Han, J., Khatwani, N., Searles, T. G., Turk, M. J., & Angeles, C. V. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101435 · Cited by 216
Stem-like exhausted and memory CD8+ T cells in cancer
Gebhardt, T., Park, S. L., & Parish, I. A. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00615-0 · Cited by 215
“including expression of CD69 and CD103 and T RM cell gene signature enrichment 57,143,146,170–172 (Fig.”
BackgroundInfluentialTGF-β in T Cell Biology: Implications for Cancer Immunotherapy
Dahmani, A., & Delisle, J.-S. (2018) · Cancers · doi:10.3390/cancers10060194 · Cited by 214
“This raises the possibility that the most effective tumor-infiltrating lymphocytes (TILs) that are stimulated through immune checkpoint blockade [142–144] or harvested and re-infused as cell therapy [145,146] are partly attracted and retained within tumor environments through TGF-β-dependent mechanisms [139].”
BackgroundWebb, J. R., Milne, K., & Nelson, B. H. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0239 · Cited by 202
“Indeed, a recent report indicates that CD103 and PD-1 are coexpressed by CD8 TIL in non–small cell lung carcinoma (38).”
BackgroundTissue‐resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance
Gebhardt, T., Palendira, U., Tscharke, D. C., & Bedoui, S. (2018) · Immunological Reviews · doi:10.1111/imr.12650 · Cited by 200
Garrido-Martin, E. M., Mellows, T. W. P., Clarke, J., Ganesan, A.-P., Wood, O., Cazaly, A., Seumois, G., Chee, S. J., Alzetani, A., King, E. V., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000778 · Cited by 196
CD74 and intratumoral immune response in breast cancer
Wang, Z.-Q., Milne, K., Webb, J. R., & Watson, P. H. (2017) · Oncotarget · doi:10.18632/oncotarget.8610 · Cited by 202
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers
Hanada, K.-I., Zhao, C., Gil-Hoyos, R., Gartner, J. J., Chow-Parmer, C., Lowery, F. J., Krishna, S., Prickett, T. D., Kivitz, S., Parkhurst, M. R., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.03.012 · Cited by 200
Immune microenvironment composition in non‐small cell lung cancer and its association with survival
Tamminga, M., Hiltermann, T. J. N., Schuuring, E., Timens, W., Fehrmann, R. S., & Groen, H. J. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1142 · Cited by 201
Zeng, D.-Q., Yu, Y.-F., Ou, Q.-Y., Li, X.-Y., Zhong, R.-Z., Xie, C.-M., & Hu, Q.-G. (2016) · Oncotarget · doi:10.18632/oncotarget.7282 · Cited by 192
“Six studies [21, 25, 30, 35, 37, 38] concerned CD3+ T lymphocytes, six studies [14, 16, 19, 22, 28, 33] were of CD4+ T lymphocytes, and six studies reported on FoxP3+ T lymphocytes [13, 21, 27, 31, 33, 34].”
ResultTissue-Resident Memory CD8+ T Cells: From Phenotype to Function
Topham, D. J., & Reilly, E. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00515 · Cited by 187
“CD103+ tumor-infiltrating CD8+ T cells are more capable of killing tumor cells (50).”
BackgroundTissue-Resident Memory T Cells in Cancer Immunosurveillance
Park, S. L., Gebhardt, T., & Mackay, L. K. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.06.002 · Cited by 193
T lymphocyte subsets in cancer immunity: Friends or foes
Chraa, D., Naim, A., Olive, D., & Badou, A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.mr0318-097r · Cited by 172
Targeting regulatory T cells by curcumin: A potential for cancer immunotherapy
Shafabakhsh, R., Pourhanifeh, M. H., Mirzaei, H. R., Sahebkar, A., Asemi, Z., & Mirzaei, H. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104353 · Cited by 188
Corgnac, S., Malenica, I., Mezquita, L., Auclin, E., Voilin, E., Kacher, J., Halse, H., Grynszpan, L., Signolle, N., Dayris, T., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100127 · Cited by 182
Self-citationThe function and dysfunction of memory CD 8+ T cells in tumor immunity
Reading, J. L., Gálvez‐Cancino, F., Swanton, C., Lladser, A., Peggs, K. S., & Quezada, S. A. (2018) · Immunological Reviews · doi:10.1111/imr.12657 · Cited by 180
CD8+ T cells and NK cells: parallel and complementary soldiers of immunotherapy
Rosenberg, J., & Huang, J. (2018) · Current Opinion in Chemical Engineering · doi:10.1016/j.coche.2017.11.006 · Cited by 175
Tissue-resident immune cells in humans
Gray, J. I., & Farber, D. L. (2022) · Annual Review of Immunology · doi:10.1146/annurev-immunol-093019-112809 · Cited by 181
Chemical Strategies to Boost Cancer Vaccines
Li, W.-H., & Li, Y.-M. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00833 · Cited by 173
Komdeur, F. L., Prins, T. M., van de Wall, S., Plat, A., Wisman, G. B. A., Hollema, H., Daemen, T., Church, D. N., de Bruyn, M., & Nijman, H. W. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1338230 · Cited by 168
“8) 0 (0) 0 (0) 0 (0) 0 (0) 52 (1-367) 83 (7-286) 80 (10-203) 0 (0) 77 (22.”
Corgnac, S., Boutet, M., Kfoury, M., Naltet, C., & Mami-Chouaib, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01904 · Cited by 163
“Expression of granzyme A, granzyme B, and perforin by CD8+CD103+ TIL was also observed at the protein level, together with the CD107a (LAMP-1) degranulation marker and the Ki-67 proliferation marker (15, 28, 45, 60).”
BackgroundInfluentialSelf-citationZhivaki, D., Borriello, F., Chow, O. A., Doran, B., Fleming, I., Theisen, D. J., Pallis, P., Shalek, A. K., Sokol, C. L., Zanoni, I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108381 · Cited by 163
“, 2018), accumulate at the tumor site in various cancer tissues and correlate with a favorable clinical outcome (Webb et al., 2014; Djenidi et al., 2015; Park et al., 2019).”
BackgroundCD103 and Intratumoral Immune Response in Breast Cancer
Wang, Z., Milne, K., Derocher, H., Webb, J. R., Nelson, B. H., & Watson, P. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0732 · Cited by 169
“Nevertheless, our studies in ovarian cancer show that the majority of CD103 positive cells are CD8 T cells and similar findings were reported in lung, colorectal and bladder cancer (13-16).”
ResultPD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells
Balança, C.-C., Salvioni, A., Scarlata, C., Michelas, M., Gomez‐Roca, C., Gomez‐Roca, C., Sarradin, V., Tosolini, M., Valle, C., Pont, F., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.142513 · Cited by 173
“We and others found that exhausted CD8 TILs express the Trm markers CD103, CD69, and CD49a (7, 8, 21).”
The evolving role of tissue-resident memory T cells in infections and cancer
Yenyuwadee, S., Lopez, J. L. S.-T., Shah, R., Rosato, P. C., & Boussiotis, V. A. (2022) · Science Advances · doi:10.1126/sciadv.abo5871 · Cited by 178
Sun, D.-Y., Hu, Y.-J., Li, X., Peng, J., Dai, Z., & Wang, S. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113392 · Cited by 173
Liikanen, I., Lauhan, C. R., Quon, S., Omilusik, K. D., Phan, A. T., Bartrolí, L. B., Ferry, A., Goulding, J., Chen, J., Scott-Browne, J. P., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143729 · Cited by 167
“Notably, Trm-like CD8+ TILs isolated from lung cancer patients readily responded to PD-1 blockade in a CD103dependent fashion (18).”
BackgroundTew, G. W., Hackney, J. A., Gibbons, D. L., Lamb, C. A., Luca, D., Egen, J. G., Diehl, L. J., Anderson, J. E., Vermeire, S., Mansfield, J. C., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.10.041 · Cited by 163
Boddupalli, C. S., Bar, N., Kadaveru, K., Krauthammer, M. O., Pornputtapong, N., Mai, Z., Ariyan, S., Narayan, D., Kluger, H. M., Deng, Y., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88955 · Cited by 157
“Enrichment of PD-1 within CD8+CD103+ T cells was previously described in the setting of surgically resected lung cancer (7).”
BackgroundUnique transcriptional and protein-expression signature in human lung tissue-resident NK cells
Marquardt, N., Kekäläinen, E., Chen, P., Lourda, M., Wilson, J. N., Scharenberg, M., Bergman, P., Al‐Ameri, M., Hård, J., Mold, J. E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11632-9 · Cited by 168
CD4+ T cells in antitumor immunity
Montauti, E. I., Oh, D. Y., & Fong, L. H. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.009 · Cited by 182
Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
Banchereau, R., Chitre, A. S., Scherl, A., Wu, T. D., Patil, N. S., de Almeida, P. E., Kadel, E. E., Madireddi, S., Au‐Yeung, A., Takahashi, C., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002231 · Cited by 161
Low lymphocyte count and high monocyte count predicts poor prognosis of gastric cancer
Feng, F., Zheng, G., Wang, Q., Liu, S., Liu, Z., Xu, G., Wang, F., Guo, M., Lian, X., & Zhang, H. (2018) · BMC Gastroenterology · doi:10.1186/s12876-018-0877-9 · Cited by 165
The Multifaceted Role of Tissue-Resident Memory T Cells
Christo, S. N., Park, S. L., Mueller, S. N., & Mackay, L. K. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101320-020220 · Cited by 154
Workel, H. H., Komdeur, F. L., Wouters, M. C. A., Plat, A., Klip, H. G., Eggink, F. A., Wisman, G. B. A., Arts, H. J. G., Oonk, M. H. M., Mourits, M. J. E., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.026 · Cited by 145
“While not examined exhaustively, our data suggest that CD103+ CD8+ T cells from adenocarcinoma uterine tumors are predominantly of an antigen-experienced effector memory phenotype, a phenotype that has also been reported in other malignancies.(13)”
ResultCui, J.-H., Lin, K.-R., Yuan, S.-H., Jin, Y.-B., Chen, X., Su, X.-K., Jiang, J., Pan, Y.-M., Mao, S.-L., Mao, X., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02729 · Cited by 181
Niches for the Long-Term Maintenance of Tissue-Resident Memory T Cells
Takamura, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01214 · Cited by 146
“CD103-mediated efficient interaction of CD8+ TRM TIL with tumor cells of epithelial origin also promotes prolonged survival and enhanced CTL activity (251, 254, 258, 259).”
BackgroundTissue-Specific Roles of NKT Cells in Tumor Immunity
Terabe, M., & Berzofsky, J. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01838 · Cited by 139
Tissue-resident lymphocytes: from adaptive to innate immunity
Sun, H., Sun, C., Xiao, W., & Sun, R. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0192-y · Cited by 145
“In addition, CTLs from CD103 tumors in lung cancer display features of enhanced cytotoxicity,(99) and CD103CD8 TILs from nonsmall-cell lung carcinoma (NSCLC) patients display increased activation-induced cell death and specific cytolytic activity toward autologous tumor cells.(102) One of the major functions of TRM ce…”
BackgroundInfluentialCD39 Identifies the CD4+ Tumor-Specific T-cell Population in Human Cancer
Kortekaas, K. E., Santegoets, S. J. A. M., Sturm, G., Ehsan, I., van Egmond, S. L., Finotello, F., Trajanoski, Z., Welters, M. J. P., van Poelgeest, M. I. E., & van der Burg, S. H. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0270 · Cited by 144
“The search for an optimal marker to dissect bystander activated T cells that coinfiltrate tumor tissue from tumor-reactive T cells, led to the realization that TILs expressing the tissue-resident marker CD103 (43) and the chronic local antigen stimulation marker CD39 (11) may be enriched for tumor-reactive T cells.”
BackgroundFederico, L., McGrail, D. J., Bentebibel, S.-E., Haymaker, C., Ravelli, A., Forget, M., Karpinets, T. V., Jiang, P., Reuben, A., Negrao, M. V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.021 · Cited by 146
Knight, F. C., Gilchuk, P., Kumar, A., Becker, K. W., Sevimli, S., Jacobson, M. E., Suryadevara, N., Wang-Bishop, L., Boyd, K. L., Crowe, J. E., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00326 · Cited by 141
Metabolic programs of T cell tissue residency empower tumour immunity
Reina-Campos, M., Heeg, M., Kennewick, K., Mathews, I. T., Galletti, G., Luna, V., Nguyen, Q., Huang, H., Milner, J. J., Hu, K. H., et al. (2023) · Nature · doi:10.1038/s41586-023-06483-w · Cited by 132
Oja, A. E., Piet, B., van der Zwan, D., Blaauwgeers, H., Mensink, M., de Kivit, S., Borst, J., Nolte, M. A., van Lier, R. A. W., Stark, R., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02654 · Cited by 130
Bi, K., Wei, X.-G., Qin, X., & Li, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00424 · Cited by 132
“As a heterogeneous tumor, NSCLC was consistently known as a non-immunogenic tumor.”
BackgroundInfluentialA local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Wu, Y., Biswas, D., Usaite, I., Angelova, M., Boeing, S., Karasaki, T., Veeriah, S., Czyzewska-Khan, J., Morton, C., Joseph, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00376-z · Cited by 140
PD-1+CD8+ T cells are clonally expanding effectors in human chronic inflammation
Petrelli, A., Mijnheer, G., van Konijnenburg, D. P. H., van der Wal, M. M., Giovannone, B., Mocholi, E., Vazirpanah, N., Broen, J. C., Hijnen, D., Oldenburg, B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96107 · Cited by 126
“Features of Trm cells, such as transcriptional profile (29, 30, 32), partial overlap with tumor-derived CD8 + TIL, expression of typical surface (retention) markers (i.e., CD69 and CD103), downregulation of S1PR1 (33), and upregulation of specific negative costimulatory markers as well as the…”
Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Tu, E., McGlinchey, K., Wang, J., Martin, P., Ching, S., Floc’h, N., Kurasawa, J. H., Starrett, J. H., Lazdun, Y., Wetzel, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.142843 · Cited by 129
Armed and Ready: Transcriptional Regulation of Tissue-Resident Memory CD8 T Cells
Behr, F. M., Chuwonpad, A., Stark, R., & van Gisbergen, K. P. J. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01770 · Cited by 124
Liu, J., Li, F., Yü, P., Wang, L., Chen, X., Wang, D., Cao, L., Zhao, S. Q., Li, B., Kaliński, P., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4617 · Cited by 123
Transcriptional programming of tissue-resident memory CD8+ T cells
Milner, J. J., & Goldrath, A. W. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.017 · Cited by 128
Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer
Nelson, M. A., Ngamcherdtrakul, W., Luoh, S., & Yantasee, W. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09968-0 · Cited by 132
“CD103+CD69+ TRM cells make up 40% of CD8 + TILs in human breast tumors on average [102].”
BackgroundInfluentialVries, N. L. D., van Unen, V., Ijsselsteijn, M. E., Abdelaal, T., van der Breggen, R., Sarasqueta, A. F., Mahfouz, A. E., Peeters, K. C. M. J., Höllt, T., Lelieveldt, B. P. F., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318672 · Cited by 121
“Such CD8 + T cell populations have been described in ovarian cancer, 44 45 lung cancer 46 and recently in melanoma, 47 cervical carcinoma 48 and CRC, 22 23 and their presence was associated with an improved clinical prognosis.”
Metadata
- Authors
- Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F.
- Affiliations
- Université Paris-Sud (FR)
- INSERM Unité 1186 , 94805 Villejuif ,
- Institute Mutualiste Montsouris (FR)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-01
- Volume
- 194
- Issue
- 7
- Pages
- 3475-3486
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1895620535
- Cited by
- 622
- References
- 51
- Citations by year
- 2026: 34 · 2025: 61 · 2024: 51 · 2023: 55 · 2022: 63 · 2021: 81 · 2020: 72 · 2019: 70 · 2018: 66 · 2017: 27 · 2016: 28 · 2015: 13
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Gustave-Roussy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-infiltrating lymphocytes, tissue-resident memory T cells, non-small cell lung cancer, PD-1, TIM-3, immune checkpoint blockade, T cell exhaustion, intraepithelial lymphocytes, patient survival, prognostic factors, T cell cytotoxicity
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Cytotoxicity, Immunologic, Female, Humans, Immunologic Memory, Lung Neoplasms, Lymphocyte Activation, Male, Membrane Proteins, Middle Aged, Neoplasm Staging, Organ Specificity, Prognosis, Risk Factors, Antigens, CD, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, CD8 Antigens, Gene Expression Profiling, Integrin alpha Chains, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.